Cargando…

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

We studied the clinical and immunological effects of Rituximab (anti-CD20) therapy in patients with lupus nephritis. In an open clinical trial, 22 patients with active systemic lupus erythematosis and renal involvement (mainly class III and IV according to the WHO classification) that was refractory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vigna-Perez, Mónica, Hernández-Castro, Berenice, Paredes-Saharopulos, Octavio, Portales-Pérez, Diana, Baranda, Lourdes, Abud-Mendoza, Carlos, González-Amaro, Roberto
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526618/ https://www.ncbi.nlm.nih.gov/pubmed/16677395 http://dx.doi.org/10.1186/ar1954

Ejemplares similares

Rituximab is effective in the treatment of nephritis in lupus patients, refractory to conventional immunosuppressive therapy
por: Martínez, R, et al.
Publicado: (2010)

Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis
por: Suh, Chang-Hee
Publicado: (2022)

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Rituximab for treatment of severe lupus nephritis
por: Baskin, E, et al.
Publicado: (2008)

Clinical efficacy and safety of rituximab in lupus nephritis
por: Zhong, Zhiqing, et al.
Publicado: (2019)

Secukinumab on Refractory Lupus Nephritis
por: Costa, Rita, et al.
Publicado: (2021)

Induction of Th17 Lymphocytes and Treg Cells by Monocyte-Derived Dendritic Cells in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Estrada-Capetillo, Lizbeth, et al.
Publicado: (2013)

Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies
por: Petricca, Luca, et al.
Publicado: (2020)

Additional antibody suppression from rituximab added to conventional therapy in severe, refractory anti-GBM nephritis
por: Mutsaers, Pim, et al.
Publicado: (2010)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

Dramatic Response of Lupus Enteritis, Nephritis, and Pancytopenia to Plasmapheresis and Rituximab
por: Aftab, Adan, et al.
Publicado: (2022)

Safety and efficacy of rituximab in refractory pediatric Systemic Lupus Erythematosus nephritis: a single-center experience of northern Greece
por: Trachana, M, et al.
Publicado: (2011)

Management of refractory lupus nephritis: challenges and solutions
por: Yo, JH, et al.
Publicado: (2019)

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

IMMUNOLOGICAL STUDIES CONCERNING THE NEPHRITIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
por: Koffler, David, et al.
Publicado: (1967)

Neuropsychiatric Lupus and Lupus Nephritis Successfully Treated with Combined IVIG and Rituximab: An Alternative to Standard of Care
por: Cheikh, Mohamed M., et al.
Publicado: (2022)

Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE
por: Gilbert, Mileka, et al.
Publicado: (2021)

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2014)

Patients with Systemic Lupus Erythematosus Show Increased Levels and Defective Function of CD69(+) T Regulatory Cells
por: Vitales-Noyola, Marlen, et al.
Publicado: (2017)

Analysis of Sodium Chloride Intake and Treg/Th17 Lymphocytes in Healthy Individuals and Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus
por: Vitales-Noyola, Marlen, et al.
Publicado: (2018)

Levels of Pathogenic Th17 and Th22 Cells in Patients with Rheumatoid Arthritis
por: Vitales-Noyola, Marlen, et al.
Publicado: (2022)

Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia
por: Arroyo-Ávila, Mariangelí, et al.
Publicado: (2015)

Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study
por: Chavarot, Nathalie, et al.
Publicado: (2017)

Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus
por: Penha, Mariana Álvares, et al.
Publicado: (2018)

Refractory Lupus Panniculitis Treated Successfully with Rituximab: Two Cases
por: Gupta, Partisha, et al.
Publicado: (2020)

ANCA-Associated Necrotizing Glomerulonephritis Overlapping with Mesangial Proliferative Lupus Nephritis Refractory to Plasmapheresis, Steroid Pulse Therapy, and a Combination of Mycophenolate Mofetil and Rituximab
por: Sharmeen, Saika, et al.
Publicado: (2018)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Rituximab Used for the Treatment of Nonuremic Calciphylaxis: A Complication of Prolonged Steroid Use in Lupus Nephritis
por: Kahn, Cameron, et al.
Publicado: (2022)

Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study
por: Kostik, Mikhail, et al.
Publicado: (2023)

Biomarkers for Refractory Lupus Nephritis: A Microarray Study of Kidney Tissue
por: Benjachat, Thitima, et al.
Publicado: (2015)

Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis
por: Zhang, Xia, et al.
Publicado: (2021)

Treatment of refractory lupus nephritis using leflunomide: A prospective study
por: Zhang, Shuo, et al.
Publicado: (2023)

A new promising biological agent for refractory lupus nephritis: Telitacicept
por: Liu, Shuangyan, et al.
Publicado: (2023)

The Emerging Role of Renal Tubular Epithelial Cells in the Immunological Pathophysiology of Lupus Nephritis
por: Hong, Seokchan, et al.
Publicado: (2020)

Rituximab Therapy for Refractory Autoimmune Thrombocytopenia in Patients with Systemic Lupus Erythematosus
por: Atay, Didem, et al.
Publicado: (2012)

Refractory Orbital Myositis in Systemic Lupus Erythematosus A Role for Rituximab
por: Rodrigues Morais, Joana, et al.
Publicado: (2021)

Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
por: Choi, Su Jin, et al.
Publicado: (2022)

PReS-FINAL-2310: Successful rituximab treatment in a 14 year-old boy with lupus nephritis
por: Torrente-Segarra, V, et al.
Publicado: (2013)

Progression to End-Stage Renal Disease Due to IgG4-Related Nephritis Refractory to Rituximab
por: Nguyen, Tien, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dt98vuv4g6ptgrrvg3jl68ag2v